BlackRock Tech and Private Equity Term Stock Price, News & Analysis

BlackRock Technology and Private Equity Term Trust (BTX) has announced the final results of its undersubscribed tender offer. The Fund will purchase all 96,627,850 shares that were properly tendered, representing less than the maximum 50% of outstanding shares (106,669,074) initially offered.

The purchase price is set at $7.4924 per share, which equals 99.5% of the Fund's net asset value as of July 9, 2025. Payment for the tendered shares is expected to be completed around July 16, 2025.

BlackRock Technology and Private Equity Term Trust (BTX) has announced the preliminary results of its tender offer that expired on July 8, 2025. The Fund offered to repurchase up to 106,669,074 shares (50% of outstanding common shares) at 99.5% of NAV as of July 9, 2025.

According to preliminary data, shareholders tendered 96,627,850 shares. Since the tender offer was undersubscribed, the Fund expects to purchase all properly tendered shares. Final results are expected to be announced on July 9, 2025.

BlackRock Technology and Private Equity Term Trust (BTX) has announced a tender offer to repurchase up to 50% of its outstanding common shares at 99.5% of the Fund's NAV per share. The tender offer commences on June 9, 2025, and expires on July 8, 2025, at 11:59 p.m. Eastern Time, with a pricing date of July 9, 2025. If more than 50% of shares are tendered, purchases will be made on a pro rata basis. Payments are expected approximately five business days after expiration, and participating shareholders will not receive the July 2025 monthly distribution on tendered shares. The complete terms and conditions will be distributed to shareholders and filed with the SEC.

BlackRock Technology and Private Equity Term Trust (NYSE: BTX) shareholders have approved two significant strategic changes during a Special Shareholder Meeting. The first change amends the Trust's fundamental investment restriction, allowing it to concentrate investments in companies within the technology group of industries. The second modification changes the Trust's status from diversified to non-diversified under the Investment Company Act of 1940.

Brooklyn ImmunoTherapeutics is rebranding as Eterna Therapeutics, effective October 17, 2022, to focus on mRNA cell engineering therapies. This shift reflects the acquisition of an extensive patent portfolio through in-licensing agreements, including over 100 patents for key cell engineering technologies. Concurrently, the company will initiate a one-for-twenty share consolidation and trade under the new ticker symbol ERNA. Eterna aims to advance its therapeutic pipeline via strategic partnerships as it transitions to a platform company in cellular and gene editing.

BROOKLYN, July 26, 2022 – Brooklyn ImmunoTherapeutics (Nasdaq: BTX) announces results from the INSPIRE phase 2 trial of IRX-2, an immunotherapy for stage II, III, or IVA squamous cell carcinoma of the oral cavity. With 150 patients enrolled, the trial reported a median Event-Free Survival (EFS) of 48.3 months in the treatment arm, exceeding the control arm. Safety profiles showed higher adverse events in the treatment group (55.9% vs 40%). The findings indicate a potential benefit for patients not receiving chemotherapy, particularly those with advanced disease. The company plans to present these results at an upcoming conference.

Brooklyn ImmunoTherapeutics (Nasdaq:BTX) announced on June 17, 2022, that it received a notice from Nasdaq regarding non-compliance with the minimum bid price requirement of $1.00 per share. The company has 180 days until December 14, 2022, to regain compliance by achieving a minimum bid price of $1.00 for 10 consecutive business days. The notice does not immediately affect trading. Brooklyn is actively monitoring its stock price and considering options for compliance.

Brooklyn ImmunoTherapeutics, Inc. (Nasdaq:BTX) announced the appointment of four new board members effective June 5, 2022, as part of its strategic growth plan. The new members include Matt Angel, Ph.D., Gregory Fiore, MD, Nicholas Singer, and Bill Wexler, who bring extensive experience in biotechnology and finance. This transition follows the departure of four previous board members. The company aims to advance its initiatives in cytokine, gene editing, and cell therapy for cancer and genetic diseases, positioning itself for future growth.

BROOKLYN, May 31, 2022 - Brooklyn ImmunoTherapeutics has appointed Matt Angel, Ph.D., as Interim Chief Executive Officer, replacing Howard Federoff, who is leaving to pursue new ventures. Andrew Jackson joins as Chief Financial Officer. Angel's experience in cell therapy and mRNA technology is crucial for advancing Brooklyn’s development programs. The company postponed its 2022 Annual Meeting, originally set for June 7, 2022, with new dates to be announced. Brooklyn focuses on cytokine and gene editing therapies for various diseases.